FDA Grants Novel Approval for VitaSmart HOPE System
Bridge to Life™ Ltd., a leader in organ preservation innovation, has recently achieved a significant milestone in the realm of liver transplant preservation. The U.S. Food and Drug Administration (FDA) has bestowed its De Novo clearance upon the VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System. This groundbreaking clearance establishes a new regulatory classification specifically for hypothermic oxygenated perfusion in liver transplantation in the United States.
Revolutionizing Liver Transplantation Practices
This much-anticipated clearance paves the way for using the VitaSmart™ device in clinical settings. Transplant centers across the nation can now adopt HOPE protocols, which enhance the preservation of donor livers effectively following traditional cold storage methods. This advancement is expected to significantly influence the efficiency and success rates of liver transplants.
Significant Implications for Organ Preservation
Don Webber, the CEO and President of Bridge to Life™ Ltd., expressed his excitement about this transformative milestone. He emphasized that VitaSmart™ is the first FDA-cleared hypothermic oxygenated perfusion system available for liver transplantation. Furthermore, the FDA's labeling underscores its safety and effectiveness, aligning perfectly with the practices seen in real-world transplant scenarios. This innovation is set to drastically improve organ utilization rates while providing transplant programs with clinical and economic advantages.
Enhancing Donation After Circulatory Death (DCD)
A vital aspect of this development is the integration of Donation after Circulatory Death (DCD) grafts into the FDA-cleared labeling. This inclusion highlights a newfound approach to managing organ preservation, especially for DCD donors. Medical professionals are optimistic that the availability of a reliable and FDA-endorsed hypothermic oxygenated perfusion system will greatly enhance strategies around DCD liver utilization.
Clinical Outcomes and Evidence
The FDA's De Novo clearance was supported by evidence from the pivotal Bridge to HOPE clinical trial. This large-scale, multicenter study involved randomized controlled assessments at various transplant centers across the United States, encompassing various donor categories, including those classified under extended criteria. The results showcased significant improvements in graft function alongside an impressive safety profile.
Operational Benefits for Transplant Centers
The VitaSmart™ system is designed not only with clinical outcomes in mind but also to alleviate operational burdens faced by transplant centers. The FDA-approved use of this system enables better resource utilization, streamlined workflows, and a scalable approach to organ preservation. These considerations are particularly crucial as transplant programs navigate the complexities of operational efficiency while striving to optimize patient outcomes.
Commercial Strategy Moving Forward
Bridge to Life is poised to launch the VitaSmart™ system in the United States during the first quarter of 2026. To lead this crucial phase of commercialization, David Castiglioni has been appointed as the Chief Commercial Officer. With a wealth of experience in transplantation and healthcare integration, Mr. Castiglioni’s leadership is expected to significantly bolster Bridge to Life’s existing market relationships.
Engineered for Efficiency and Adoption
The VitaSmart™ system represents a sophisticated innovation, providing hypothermic oxygenated perfusion while meticulously regulating liver temperatures. Designed to be user-friendly, this technology is anticipated to enhance adoption across various transplant centers. With its FDA-cleared indication, it opens new avenues for improving patient care standards.
Gratitude to Research Teams
In closing, Don Webber expressed heartfelt gratitude towards the clinical teams, investigators, and participants involved in the Bridge to HOPE study. Their collaboration and commitment have been instrumental in reaching this pivotal moment for liver transplantation.
About Bridge to Life™ Ltd.
Bridge to Life™ Ltd. stands as a pioneering force in the field of organ preservation solutions. With a diverse portfolio that includes products such as Belzer UW®, EasiSlush®, and the new VitaSmart™ Hypothermic Oxygenated Perfusion System, the company partners with transplant centers to advance preservation science and facilitate life-saving transplants.
Frequently Asked Questions
What is the VitaSmart Hypothermic Oxygenated Perfusion System?
The VitaSmart System is a groundbreaking device cleared by the FDA for use in liver transplantation, enhancing organ preservation during the transplant process.
How does the FDA clearance impact liver grafts?
The FDA clearance allows for hypothermic oxygenated perfusion of donor livers, greatly improving outcomes for both DBD and DCD grafts.
What advantages does the VitaSmart System offer?
This system offers improved organ utilization, reduced operational complexities, and enhanced safety for transplant procedures.
When is the expected launch date for the VitaSmart System?
The commercial launch for the VitaSmart System is scheduled for the first quarter of 2026.
Who is leading the commercialization of the VitaSmart System?
David Castiglioni has been appointed as the Chief Commercial Officer to spearhead the U.S. commercialization efforts of the VitaSmart product.
